yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

The Zacks Analyst Blog Highlights: Nucor Corporation, Encana, Commercial Metals Co., United States Corp. and Merck

CHICAGO, Nov. 12, 2012 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Nucor Corporation (NUE), Encana (ECA), Commercial Metals Co. (CMC), United States Corp (X) and Merck (MRK).


Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free.

Here are highlights from Monday's Analyst Blog:

Nucor Inks Agreement with EnCana

Steel maker Nucor Corporation (NUE) entered into a deal with Canada's largest natural gas producer Encana (ECA) to develop onshore natural gas drilling program in the continental U.S. Nucor believes that the drilling program will provide a reliable, low-cost supply of fuel for more than 20 years.

Per the agreement, Nucor will share its part of costs and will also shell out an additional amount for the drilling. The agreement also has an option where either of the companies may suspend drilling if the price of natural gas falls below a predetermined threshold. Encana will provide expertise for drilling and operating the wells.

The agreement will establish a reliable gas supply for the direct reduced iron facility, which is currently under construction in Convent, Louisiana where iron ore is turned into a concentrate. The facility is expected to come online in mid 2013 and is expected to increase Nucor's usage of natural gas. The recent deal is an extension of the existing agreement between Nucor and Encana that was signed in 2010.

As per Nucor, the deal can provide enough natural gas to offset the fuel that is used at its U.S. mills and two gas-intensive direct reduced iron facilities. Nucor believes that the deal will improve its competitive position and will be beneficial for both the companies.

Last month, Nucor released its third quarter 2012 results. The company reported adjusted (excluding special items) earnings of 45 cents per share in the third quarter of 2012, ahead of the Zacks Consensus Estimate of 42 cents. The adjusted earnings exclude cost associated with Skyline Steel buyout and loss on divestiture of the assets of Nucor Wire Products Pennsylvania, Inc.

Profit (as reported) came in at $110.3 million or 35 cents a share, down 39% from $181.5 million or 57 cents per share reported a year ago. The bottom line was hurt by lower operating profits at the company's steel mills, especially in sheet and plate.

Revenues slid 8.6% year over year to $4,801 million, missing the Zacks Consensus Estimate of $4,856 million. An 8% fall in average sales price weighed on Nucor's revenues in the quarter. Total tons shipped to outside customers dipped 0.3% year over year to 5.8 million tons in the reported quarter and total mill shipments decreased 1.7% to 5.0 million tons.

The company, which competes with Commercial Metals Co. (CMC) and United States Steel Corp. (X), maintains a Zacks #3 Rank, which translates into a short-term (1 to 3 months) Hold rating. We currently have a long-term Neutral recommendation on the shares of Nucor.

FDA Accepts Merck Sleep Drug

Merck (MRK) recently announced that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its insomnia candidate, suvorexant. The agency granted standard review which means a response should be out in the second half of 2013.

Merck said that the FDA's Controlled Substance Staff will review the NDA. Once it is approved, the Drug Enforcement Administration (DEA) will assess and assign the schedule for the drug before it is launched.

Suvorexant belongs to a new class of medicines called orexin receptor antagonists which target and block orexins.

Earlier this year, Merck had presented encouraging data on suvorexant from two pivotal phase III efficacy trials. Suvorexant was shown to significantly lower the time it took for patients to fall asleep. Moreover, patients in the suvorexant arm stayed asleep longer as early as the first night as well as at the three-month time point.

Approval would make suvorexant the first orexin receptor antagonist to reach the market. However, we note that the insomnia market is highly competitive and genericized.

Merck has several more regulatory filings scheduled for the next few quarters. The company plans to seek US and EU approval for its osteoporosis candidate, odanacatib, in the first half of 2013 and in Japan in the second half of 2013.

The resubmission of the sugammadex (reversal of certain muscle relaxants used during surgery) filing in the US is also slated to take place by year end.

Other candidates for which Merck intends to seek regulatory approval in the coming months include vintafolide (oncology), Tredaptive (cholesterol management) and V503 (a vaccine that expands protection against certain HPV-associated cancers by including additional HPV types).

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Follow us on Twitter:

Join us on Facebook:

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, brokerage, market making or asset management activities of any securities. Visit for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
This is how a typical software product lifecycle works : You gather requirements, build a prototype, detail out the architecture and design, develop the product, test it, deploy the product, handle migration and maintenance and ensure product support. This is a closed loop where the Pr...
Certain CIOs for incomprehensible reasons keep off their cloud transformation projects several key IT disciplines including Enterprise Architecture (EA), IT Service Management (ITSM) and most importantly Project Management. Do they consider them obsolete? useless? irrelevant? ITaaS St...
Here’s the thing: as sure as we’ll have another record-setting year for NFL streaming, you can also be sure that apps will fail and streaming services will go down. Whether you are dabbling in streaming or diving in whole-hog, you need to know what to do to give your users the most rel...
In today’s pharmaceutical supply chain, counterfeit activity is thriving. As pharma companies have expanded target markets and outsourced production over the last decade, the supply chain has become increasingly global, virtual, and vulnerable. Illicit activity has thrived, and patient...
Intuit uses deep-data analytics to gain a 360-degree view of its TurboTax application's users’ behavior and preferences for rapid applications improvements. The next BriefingsDirect big-data innovation case study highlights how Intuit uses deep-data analytics to gain a 360-degree view...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers